Etrasimod

Mechanism of Action

Etrasimod works by targeting a molecule called sphingosine 1-phosphate (S1P). S1P has various roles in the body, including regulating the movement of immune cells, particularly lymphocytes. There are five types of S1P receptors (S1P1-5), and etrasimod binds with high affinity to three of them: S1P1, S1P4, and S1P5.

Here's a breakdown of how etrasimod affects lymphocytes:

Blocks lymphocyte egress: Normally, S1P signals lymphocytes to leave the lymph nodes and enter the bloodstream. By binding to S1P receptors, etrasimod partially blocks this signal. This reduces the number of lymphocytes circulating in the blood.

Reduces lymphocyte migration to intestines: In ulcerative colitis, there's an abnormal activation of immune cells in the intestines. While the exact mechanism isn't fully understood, the reduced number of circulating lymphocytes due to etrasimod's action is believed to lead to fewer lymphocytes migrating into the inflamed intestinal tissue. This helps to lessen inflammation and associated symptoms.

Indication

Etrasimod is specifically indicated for the treatment of moderately to severely active ulcerative colitis in adults. It's not a cure, but it can help manage symptoms like:

Diarrhea Rectal bleeding Abdominal pain Urgent need to have a bowel movement (tenesmus) Etrasimod is typically used when other medications haven't been effective in controlling the disease.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Etrasimod API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Etrasimod API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.